Can Neural Networks Answer Diagnostic Dilemmas in Rheumatology? Presented at #ACR22, investigators wanted to establish whether neural networks can distinguish seropositive RA+, RA-, and PsA using hand MRI data based on structural inflammation patterns. https://t.co/X2zceiAQ4J https://t.co/J0VUwlVMze

PsA Cycling or Switching MOAs Dr. Tate ( @uptoTate) interviews Dr. Alexis Ogdie ( @AlexisO) at #ACR22 on Abstract 1600: The Impact of Second-Line Therapeutic on Disease Control After Discontinuation of First Line TNF Inhibitor in Patients with PsA https://t.co/S83Wbpbd4V https://t.co/B1gTmMAzc1

Gender in AxSpa Dr. Peter Nash ( @drpnash) weighs in at #ACR22. https://t.co/Utkg4Yltif https://t.co/IvZNe9BQHr

Lupus, Sex and STDs Dr. Kathryn Dao discusses abstract 0939 presented at #ACR22. https://t.co/4VyRihrpa8 https://t.co/hqsfWeUQQo

Frailty in Vasculitis Dr. Patricia Harkins ( @DrTrishHarkins) sits down with Professor Sebastian Sattui to discuss Abstract 0444, Prevalence of Frailty and Associated Factors in Patients with Vasculitis, being presented on Saturday at #ACR22. https://t.co/0Gd1cHNVlg https://t.co/blS2XvHIgS

Do biologics help taper steroids in Adult Still’s Disease? A Japanese large scale claims data study presented at #ACR22 (abstract#0826) was able to collect 5-year data to study the treatment patterns in Still’s. https://t.co/S0HMfWuUai https://t.co/ZKV0aP900w

Anifrolumab shows long-term promise in patients with lupus Researchers report positive results from the first placebo-controlled long-term trial of anifrolumab—a human monoclonal antibody that targets the type I IFN receptor—in patients with lupus. https://t.co/sYzLMgLzqy https://t.co/fdmhYONI3G

Sputum anti-CCP the new diagnostic test in at-risk RA?' Dr. Aurelie Najm ( @AurelieRheumo) discusses abstract 0533 at #ACR22. https://t.co/DNKVmPjmh9 https://t.co/b5x26PzzS5

Sarilumab in Polymyalgia Rheumatica: Results from SAPHYR Trial Dr. Michael Putman interviews Dr. Robert Speira about abstract 1676 presented at #ACR22. https://t.co/nJAOBDC8KX https://t.co/Tgls8O4AVC